A great leap forward in the war against Alzheimer’s disease
A great leap forward in the war against Alzheimer’s disease
The approval of the first drug to treat the neurodegenerative disease in 18 years will galvanise research in the entire subsector, says Dr Mike Tubbs.…
16 Jul 2021
Shake-up at GSK won’t placate investors
Shake-up at GSK won’t placate investors
GSK has launched a radical shakeup of its operations, but that's unlikely to satisfy investors unhappy with the drugmaker's perennial underperformance…
2 Jul 2021
Two investment trusts that have proved their worth
Two investment trusts that have proved their worth
These two investment trusts have earned investors’ confidence since their flotations and remain solid bets, says Max King.
25 Jun 2021
Investing in stem cells, the building blocks of the body
Investing in stem cells, the building blocks of the body
Stem cells have always been tomorrow’s technology. But it looks as though their time has finally come – and they will transform the treatment of disea…
18 Jun 2021
Why Joe Biden’s Big Pharma patent grab is a terrible idea
Why Joe Biden’s Big Pharma patent grab is a terrible idea
The US president has proposed waiving patents on Covid-19 vaccines in a bid to boost global supply. But it won’t work on its own terms and holds dange…
22 May 2021
A show of support for GlaxoSmithKline's hedge fund fight
A show of support for GlaxoSmithKline's hedge fund fight
Several large shareholders have said that they will support GlaxoSmithKline in its battle with hedge fund Elliott Management.
21 May 2021
How to invest in biotechnology: the healthcare sector’s high-growth area
How to invest in biotechnology: the healthcare sector’s high-growth area
Dr Mike Tubbs provides an overview of this thriving industry, whose latest triumphs include the Covid-19 vaccines. He examines the best investment str…
14 May 2021
Subscribe to MoneyWeek and get your first six issues FREE
Subscribe to MoneyWeek now and get your first six magazine issues absolutely FREE
Vaccine patents: a bitter pill for drug companies
Vaccine patents: a bitter pill for drug companies
The US has suggested waiving drug companies’ vaccine patents to hasten the defeat of Covid-19, sending their share prices down.
14 May 2021
AstraZeneca’s shareholders rebel over pay
AstraZeneca’s shareholders rebel over pay
Shareholders in AstraZeneca have rebelled over proposals to raise bonus levels for its bosses.
14 May 2021
Merck: the good value biotech stock that has cornered the cancer market
Merck: the good value biotech stock that has cornered the cancer market
Merck, the biopharma giant, dominates the biggest disease sector and looks reasonably valued, says Dr Mike Tubbs.
27 Apr 2021
Activist investor Elliott takes takes a stake in Glaxo
Activist investor Elliott takes takes a stake in Glaxo
Elliott, s US hedge fund, took an undisclosed multibillion-pound stake in GSK last week, driving the share price up by 4.6%.
22 Apr 2021
Get decades of growth at a discount with this healthcare investment trust
Get decades of growth at a discount with this healthcare investment trust
Healthcare is set for strong long-term expansion but looks cheap. That makes this investment trust worth buying, says Max King.
19 Apr 2021
Moderna’s Stéphane Bancel: the maths nerd who struck vaccine gold
Moderna’s Stéphane Bancel: the maths nerd who struck vaccine gold
A decade ago, Stéphane Bancel took a gamble and joined a fledgling start-up working on an unproven new technology. The gamble paid off with the rise o…
17 Apr 2021
How the vaccine wars will harm us all
How the vaccine wars will harm us all
Grabbing and hoarding vaccine supplies, or even manufacturing one’s own, might seem to make sense for a state in an emergency. But the damage done to …
27 Mar 2021
AstraZeneca’s Pascal Soriot: in the crossfire of the vaccine wars
AstraZeneca’s Pascal Soriot: in the crossfire of the vaccine wars
AstraZeneca’s boss Pascal Soriot was winning plaudits for his stewardship when the Covid-19 pandemic struck. Since then, he’s been having a hard time …
27 Mar 2021
Scientific-instrument companies are a global success – here's how to play them
Scientific-instrument companies are a global success – here's how to play them
Companies delivering scientific instruments – products to measure and analyse our world – are crucial to sectors ranging from telecommunications to ph…
26 Mar 2021
Three winners of the long-term biotech boom
Three winners of the long-term biotech boom
Professional investor Marek Poszepcynski of the International Biotechnology Trust picks three biotech stocks with good pipelines, strong management te…
22 Mar 2021
The unscientific criticism of AstraZeneca could do lasting damage
The unscientific criticism of AstraZeneca could do lasting damage
Several European countries have suspended their use of AstraZeneca's Covid vaccine – for no good scientific reason. Matthew Partridge reports.
18 Mar 2021
Johnson & Johnson vaccine approval is another shot in the arm for the world
Johnson & Johnson vaccine approval is another shot in the arm for the world
Johnson & Johnson’s vaccine has been approved in the US, a sign that the world is making solid progress against Covid-19. Matthew Partridge reports
4 Mar 2021
How to invest in the latest developments in hearing technology
How to invest in the latest developments in hearing technology
Traditionally dismissed as a relative backwater, this branch of medicine is about to move into the limelight thanks to ageing populations and major br…
19 Feb 2021
Vanquishing the virus: the race to make vaccines for Covid-19
Vanquishing the virus: the race to make vaccines for Covid-19
The extraordinarily rapid development of effective treatments against the coronavirus is a triumph of biotechnology, says Dr Mike Tubbs. He reviews th…
12 Feb 2021
Vexing vaccine delays hit drug firms
Vexing vaccine delays hit drug firms
AstraZeneca and Pfizer are being attacked by the EU over what it claims are delays in delivering the Covid vaccine.
28 Jan 2021